Close menu




April 15th, 2022 | 12:11 CEST

Deutsche Bank, wallstreet:online, Commerzbank - Financial stocks about to jump

  • Investments
Photo credits: pixabay.com

Rising and longer-lasting inflation is worrying market participants. The central banks, which held on to their ultra-loose monetary policy for too long in favor of possible economic growth, must act now. While the ECB is still in a deep sleep, the US Federal Reserve started with the first interest rate hikes, and more will follow. The beneficiaries of the interest rate turnaround are financial institutions, which also performed after the announcements. However, the war in Ukraine knocked them back. A possible second chance to invest in attractive financial service providers.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: DEUTSCHE BANK AG NA O.N. | DE0005140008 , WALLSTREET:ONLINE INH ON | DE000A2GS609 , COMMERZBANK AG | DE000CBK1001

Table of contents:


    Inflation is considerably too high

    The ECB's inflation target is 2%. For March, the Federal Statistical Office has now put it at 7.3%. Inflation was influenced by supply bottlenecks and significant price increases at upstream economic stages. Energy products, in particular, and other goods and services, became more expensive due to the current crises. "In addition to the Corona pandemic, Russia's war against Ukraine is now having a significant impact on inflation in Germany, particularly for heating oil, fuels and natural gas, as well as individual foodstuffs," says Dr. Georg Thiel, President of the Federal Statistical Office. Not only economists are now calling on the ECB to raise interest rates quickly and significantly.

    In contrast, the key interest rate remains at 0%. Only the volume of the APP bond-buying program will be capped again at EUR 20 billion at the end of June after a temporary increase. ECB President Christine Lagarde said that an interest rate hike could come "some time" after the expiration of bond purchases in the third quarter. The US is at least a step ahead here and has already announced further steps after the first interest rate hike. Shares of banks and financial service providers such as Deutsche Bank and Commerzbank were able to profit significantly since the beginning of the year, when the change in strategy became clear, and marked new 4-year highs until mid-February. However, the positive run was then abruptly halted by the Russian invasion.

    Investors press "sell"

    Fears of high credit exposure from Russia and Ukraine destroyed the positive chart picture. Deutsche Bank fell by around 44% from EUR 14.63 to EUR 8.16 within days, while Commerzbank lost roughly the same amount in market capitalization. The exaggerated correction was partially made up, but at the beginning of this week, the next bad news came at the same time for both financial institutions.

    Capital Group, one of the major shareholders along with BlackRock, is believed to have placed 116 million Deutsche Bank shares through the US investment bank Morgan Stanley, at a price of EUR 10.08, which is almost 8% below the current share price at the time. These figures were reported by the news channel Bloomberg. At the same time, 72.5 million Commerzbank shares changed hands at EUR 6.65, almost 7% below the price. The total proceeds amounted to EUR 1.75 billion. Due to the substantial price losses, both banks offer attractive long-term entry opportunities. However, the shares could come under renewed pressure in the short term due to the uncertain geopolitical situation. The respective annual lows could be considered as the target.

    Bullish indicators

    The Berlin wallstreet:online Group could already have a sell-off behind it. After the stock had already started its correction last year in the course of the weakening general market, Russia's invasion of Ukraine prompted what was probably the final sell-off with a low of EUR 14.30, around 50% off from the all-time high. Since then, the share price has gradually recovered, and a significant buy signal would be generated if the resistance at EUR 18.20 were exceeded.

    In contrast to the share price performance, wallstreet:online AG, which owns 100% of the operating company of the successful Smartbroker, is running like clockwork. Thus, the operating company w:o Capital is the largest neobroker operating company in Germany with more than EUR 8.8 billion in "assets under custody". In addition, the Group achieved a new revenue record of EUR 51.4 million, up 82% YOY. Preliminary adjusted EBITDA before customer acquisition costs for Smartbroker grew by 45% to EUR 17.5 million. The Group's net cash position at year-end 2021 was approximately EUR 20 million.

    Keeping on the gas pedal

    The current fiscal year 2022 will be crucial for the Capitals. Thus, the focus is on the implementation of its "Smartbroker Cloud Platform" and the acceleration of the new "Smartbroker 2.0". On the figures side, wallstreet:online expects revenues of between EUR 62 million and EUR 67 million, which would mean an increase of around 25% YOY. Adjusted EBITDA after customer acquisition costs is expected to be between EUR 10 million and EUR 12 million. The analyst firm GBC AG sees an acceleration of the growth rate and a significant increase in profitability due to the planned optimization of the brokerage business model with the help of its Smartbroker Cloud Platform. The study, published at the end of March, was rated "buy," and the price target was raised to EUR 38.60.


    Banks and financial service providers should benefit in the long term from the change in monetary policy strategy. Both Commerzbank and Deutsche Bank are still in the midst of their, so far successful, restructuring process. wallstreet:online has enormous potential due to "Smartbroker 2.0."


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read